EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients

•63 tumor samples were analyzed for EGFR and KRAS mutation out of 73 HIV-NSCLC.•EGFR mutations were identified in two patients (3.3%).•Proportion of KRAS mutations was 29% using the more sensitive molecular techniques.•EGFR mutations exhibited lasting partial response to EGFR-tyrosine kinase inhibitors.•KRAS mutation is of poor prognostic value.